Role of Embolic Protection in Percutaneous Coronary Intervention without Saphenous Venous graft lesions in ST-elevation myocardial infarction - a systematic review and meta-analysis

Maisha Maliha; Vikyath Satish; Kuan Yu Chi; Diego Barzallo Zeas; Amrin Kharawala; Nathaniel Abittan; Sneha Nandy; Nidhi Madan; Prabhjot Singh; Eleonora Gashi

doi:10.1097/HPC.0000000000000376

Role of Embolic Protection in Percutaneous Coronary Intervention without Saphenous Venous graft lesions in ST-elevation myocardial infarction - a systematic review and meta-analysis

Crit Pathw Cardiol. 2024 Oct 1. doi: 10.1097/HPC.0000000000000376. Online ahead of print.

Authors

Maisha Maliha^{1

2}, Vikyath Satish^{1

2}, Kuan Yu Chi^{1

2}, Diego Barzallo Zeas^{1

2}, Amrin Kharawala^{1

2}, Nathaniel Abittan³, Sneha Nandy⁴, Nidhi Madan⁵, Prabhjot Singh^{1

2}, Eleonora Gashi^{1

2}

Affiliations

¹ -Jacobi Medical Center Department of Medicine 1400 Pelham Pkwy S, Bronx, New York 10461.
² Albert Einstein College of Medicine Department of Medicine 1300 Morris Park Ave, Bronx,NY 10461.
³ Westchester Medical Center 100 Woods Rd, Valhalla, NY 10595.
⁴ University of Mississippi Medical Center 2500 N State St, Jackson, MS 39216.
⁵ UnityPoint Health-St Luke's Heart Care 202 10th Street Southeast, Cedar Rapids, IA 52403.

PMID: 39345009
DOI: 10.1097/HPC.0000000000000376

Abstract

Introduction: Embolic protection devices are catheter-based devices that can be used to capture atherosclerotic remnants released during percutaneous coronary intervention (PCI). We aim to study the efficacy and safety of EPDs in PCIs without saphenous vein grafts (SVG) in ST-elevation myocardial infarction(STEMI).

Methods: 3 electronic databases of MEDLINE, Web of Science, and Embase were searched from inception to Apr 10, 2024, to identify relevant randomized controlled trials (RCTs) that compared outcomes of patients subjected to EPD during PCI with control group where EPDs were not utilized. The primary outcome was 30-day all-cause mortality. Secondary outcomes were major adverse cardiovascular and cerebrovascular events (MACCE) at 30 days, post-PCI Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow attainment, ST-segment resolution at 90 minutes post-procedure and post-procedure angiographically detectable signs of distal embolization. The effect estimates of outcomes were assessed using risk ratio (RR) with a 95% confidence interval (CI). Random-effects meta-analysis was conducted using the restricted maximum likelihood method given the inter-study variance was inevitable.

Results: We included 3 RCTs enrolling 741 patients (age 61.6 ± 12.15 years, 22% females) undergoing PCI without SVG lesions. As opposed to the control group, the use of EPD did not yield a significant effect on all-cause mortality (RR, 0.76; 95% CI, 0.31-1.86; I 2 = 0%), MACCE (RR, 0.66; 95% CI, 0.34-1.27; I 2 = 0%), post-PCI TIMI 3 flow (RR, 1.18; 95% CI, 0.86-1.62; I 2 = 77%) and ST segment resolution at 90 minutes post-procedure (RR, 1.05; 95% CI, 0.90-1.22; I 2 = 0%). However, EPD significantly decreased angiographically detectable signs of distal embolization (RR, 0.60; 95% CI, 0.36 to 0.99; I 2 = 0%).

Conclusions: EPD significantly reduced angiographically detectable signs of distal embolization in PCI without SVG lesions in STEMI, though there were no clinical signs of improved flow or mortality. Further trials are necessary to thoroughly evaluate the potential benefits and requirements of EPD usage in such procedures.